|Day Low/High||5.11 / 5.34|
|52 Wk Low/High||1.63 / 15.96|
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the December 15th expiration.
A Treatment for Relapsed/Refractory Peripheral T-Cell Lymphoma
Esperion Therapeutics, Minerva Neurosciences and BioCryst Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.
Spectrum Pharmaceuticals, BioCryst Pharmaceuticals and Curis were among the biotech stock movers in premarket trading on Thursday.
In recent trading, shares of BioCryst Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $7.78, changing hands for $7.80/share.
BioCryst's Hereditary angioedema drug-trial results not compelling.
Current drugs approved to prevent and reduce the frequency of HAE swelling attacks require injections, so BioCryst's once-daily pill has the potential to be more convenient.
BioCryst Pharmaceuticals, Sangamo Therapeutics and Cempra were among the biotech stock movers in premarket trading on Monday.
Shares of BioCryst (BCRX) fell double digits despite topping analysts' 4Q expectations.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioCryst Pharmaceuticals, Inc. , where a total of 16,282 contracts have traded so far, representing approximately 1.6 million underlying shares.
Progenics, Alexion and BioCryst were among the biotech stock movers in premarket trading on Thursday.
Synergy Pharmaceuticals, Arrowhead Pharmaceuticals and BioCryst Pharmaceuticals were among the biotech stock movers in premarket trading on Wednesday.
Investors considering a purchase of BioCryst Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $5.90/share, might benefit from considering selling puts among the alternative strategies at their disposal.
The number of new 12-month highs has climbed to 240.
The euphoria has calmed down, and if stocks can consolidate, we will have some better entry points.